Cat. No. 5595
Chemical Name: (2S)-N1-[2-(1,1-Dimethylethyl)-4'-me
Biological ActivityPotent and selective PI 3-kinase p110α inhibitor (IC50 = 32 nM). Exhibits >100-fold selectivity for p110α over other PI 3-kinase isoforms. Inhibits Akt signaling and tumor growth in SK-OV-3 xenografts in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Jamieson et al (2011) A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem. J. 438 53. PMID: 21668414.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses A66 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: A66, supplier, PI, 3-kinase, PI3K, phosphoinositide, 3-kinase, inhibitors, potent, selective, inhibits, p110a, alpha, α, Tocris Bioscience, PI 3-kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitorEnzastaurin
Potent PKCβ inhibitorBMS 265246
Potent cdk1/2 inhibitorAutocamtide-2-related inhibitory peptide, myristoylated
CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide
April 1 - 5, 2017
Washington, D.C., USA